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a  b  s  t  r  a  c  t
Objective: To describe the pain in patients infected with human T-cell lymphotropic virus
type 1, clinically and epidemiologically.
Methods: This systematic review was based on The PRISMA Statement. Four reviewers
searched PUBMED, SciELO, LILACS and BIREME for data from observational studies and
clinical trials (n ≥ 30) regarding pain prevalence, characteristics, and associated factors in
patients with human T-cell lymphotropic virus type 1. No limits on publication date or
language were established. Studies that did not have pain as an outcome measure or not
involving human T-cell lymphotropic virus type 1 infected patients were excluded.
Results: A total of 3013 articles (including duplicates) were found of which seven met
the  predetermined criteria. The most common pain region was the lower back (53.0%).
Non-neuropathic type (ranging from 52.6% to 86.8%) was more frequent in human T-cell
lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis participants,and  neuropathic pain was more common in human T-cell lymphotropic virus type 1 car-
riers (53.1%). The pain was mostly reported as moderate or severe. One study showed that
chronic pain was negatively associated with quality of life.
Discussion: Pain is a common complaint in human T-cell lymphotropic virus type 1infected patients, with lower back pain as the most frequent site. Pain can either be
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nociceptive, neuropathic, or both, is frequently severe, and negatively affects quality of life.
Only studies of two countries were included in this review, limiting the external validity of
the  conclusions. The heterogeneity of variables prevented us from implementing a meta-
analysis. Further research should better characterize the pain and explore its impact on
quality of life, especially using longitudinal study design.
©  2016 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. This is









































he human T-cell lymphotropic virus type 1 (HTLV-1) is a
etrovirus that can be transmitted by sexual contact, shared
eedles and syringes, blood transfusions, through the pla-
enta, or during breastfeeding.1,2 The prevalence of HTLV-1
s still unknown, although it is estimated that 10–20 million
eople worldwide carry the virus.1
The chance of an infected asymptomatic individual to
evelop HTLV-1-associated myelopathy/tropical spastic para-
aresis (HAM/TSP) ranges between 1 and 5%.3 The prevalence
s higher in the Caribbean and South American countries
4%) than in Japan (0.25%). The average prevalence is 2% in
atin America. Therefore, it is estimated that 100,000 cases of
AM/TSP exist worldwide, making this spectrum of HTLV-1 a
ublic health concern in this part of the world.4,5
Nociceptive pain (resulting from inﬂammatory mediators)
nd neuropathic pain (secondary from injury and/or dys-
unction of the somatosensory system) are frequent, as well
s other sensory disturbances.4,6 There are also reports of
n association between HTLV-1 infection and rheumatic dis-
ases such as Sjogren’s syndrome, rheumatoid arthritis, and
bromyalgia.7
Although many  studies attempted to characterize pain in
TLV-1 infected patients,8–12 it is not clear whether it is a focal
anifestation of the neurological complex or a systemic dis-
ase, such as other diffuse pain syndromes. To answer these
uestions, it is important to clarify some relevant issues that
emain unclear, such as general prevalence/frequency, the
ffected sites, associated factors and the most frequent nature
f pain (neuropathic or nociceptive) in this disabling condition.
he goal of this study was to review the literature regarding
ain characteristics and associated factors in patients with
TLV-1.
aterials  and  methods
his systematic review was based on the PRISMA Statement
or reporting systematic reviews and metanalyses. Four inde-
endent reviewers searched PubMed, SciELO, BIREME and
ILACS. The search was conducted from October 2014 until
anuary 2016. The search strategy is described in Appendix A.
This review included cross-sectional and cohort studies,
n addition to baseline data from clinical trials when it was
easible to extract information regarding pain prevalence and
ssociated factors in HTLV-1 infected patients. No language or
ublication date restrictions were imposed. The studies hadlicenses/by-nc-nd/4.0/).
to involve more  than 30 participants, aged more  than 18 years
old, with a clear deﬁnition of HTLV-1 or HAM/TSP diagnos-
tic criteria. Other study designs, studies not involving pain
as an outcome measure, inclusion of other infections such as
human immunodeﬁciency virus or HTLV-2, and studies involv-
ing other neurological diseases were excluded.
Articles were ﬁrst screened by title, and then by abstract.
Full texts of potentially eligible studies were read and eligi-
bility criteria were applied. Disagreement about the inclusion
or exclusion of a certain study were resolved by consensus
meeting. Data collected from each paper included: (a) pain
prevalence in HTLV-1 infected participants; (b) clinical pain
description; (c) age, gender, race/ethnicity, socioeconomic sta-
tus, and educational level; and (d) number of participants. Risk
of bias focused on speciﬁcations of how many  participants
were lost to follow up, and whether the authors had a conﬂict
of interest.
The Newcastle-Ottawa Scale (NOS)13 was used to assess
the quality of the included studies, according to their basic
designs. The scale includes three domains, with a maximum
score (stars) for each of them. The domain of selection (maxi-
mum of 5 stars) includes the representativeness of the sample,
sample size, non-respondents, and ascertainment of the expo-
sure. The domain of comparability (maximum of 2 stars)
includes the comparability between the groups. The outcome
domain (3 stars) includes the assessment of the outcome and
the statistical test. This scale classiﬁes the articles from one
star (low quality) to 10 stars (high quality). The maximum
punctuation changes according to each study design (nine
points for cohort and case-control studies and 10 points for
cross-sectional studies).
Results
The database search yielded 3013 citations, until January
2016, including duplicates (Fig. 1). Seven studies met  the pre-
determined criteria1,6,8–12: six studies were identiﬁed from the
database search and one study was found after a manual
search (Table 1). These studies were published between 2005
and 2013. No clinical trial was included in this review. The
total number of participants was 575. Approximately 70% of
the included subjects were women, mean age ranging from 40
to 51 years, most of them classiﬁed as non-white (Table 1), and
from a low socioeconomic and educational status.8–10All participants were recruited at HTLV-1 reference centers
and were diagnosed according to basic procedures includ-
ing enzyme-linked immunosorbent assay (ELISA), polymerase
chain reaction and Western blot conﬁrmation.1,6,8–12 The




959 exc luded dupli cates
1562  stud ies exc luded  be cau se
they did not involve the topic and
415 case repo rts and  reviews
14 arti cles met the  crit eria by
read ing  the  ab stract
3013  stud ies found in PubMed; SciELO;
BIREME;  LILACS
Selected 2054 studies
77 stud ies selected  aft er read ing
the t itle
Excluded 63 articles: 19 papers  did not co ver
the top ic, 20  reviews and  commen ts, 22
articles with sa mples aged <30  or unde r 18
years. Two pape rs included  coinfection  wit h
HIV
Excluded  eight  arti cles due t o
coinfection with HIV and HTLV-2 not
previou sly seen  by read ing the titl e
Six  arti cles aft er read ing f ull t ext
Seven  arti cles final
sample
Add  one article by read ing
the  stud ies referen ces
Fig. 1 – Selection of the included articles. HIV, human immunodeﬁciency virus; HTLV-2, human T-cell lymphotropic virus
type 2.
Table 1 – Demographic characteristics of subjects of the included studies.
Author, year n Country Population Study design Gender (%females) Age (range) Race/ethnicity (%)
Martin et al., 2010 41 UK HAM/TSP Cohort 79.2 51 ± 46–55 White (12.5)
Black (79.2)
Poetker et al., 2011 142 Brazil HTLV-1a Case-control 63.4 40.2 ± 11.7 White (21.7)
Black (49.3)
Franzoi and Araujo, 2005 72 Brazil HAM/TSP Cross sectional 68.0 51.1 ± 12.1 –
Franzoi and Araujo, 2007 72 Brazil HAM/TSP Cross-sectional 68.0 51.1 ± 12.1 –
Tavares et al., 2010 90 Brazil HAM/TSP Cross-sectional 70.0 36.7 ± 15.4 –
Netto and Brites, 2011 43 Brazil HAM/TSP Cross-sectional 72.1 45.3 ± 13.3 White (16.3)
Non-white (83.7)
Mendes et al., 2013 115 Brazil HTLV-1 Cross-sectional 69.6 48.5 ± 13.6 White (12.2)
Black (46.1)
n, number of participants; UK, United Kingdom; HTLV-1, human T lymphotropic virus-1; HAM/TSP, HTLV-1 associated myelopathy/tropical
spastic paraparesis.
a This study excluded HAM/TSP participants.
World Health Organization’s (WHO) guideline was used to
identify HAM/TSP in six studies (F. Martin, MD, PhD, unpub-
lished data, July, 2015).1,6,8,10–12 Two studies also used De
Castro-Costa classiﬁcation.8,10 One paper did not include
HAM/TSP participants.9 According to the NOS, three papers
were classiﬁed as of good or very good quality, and four were
unsatisfactory (Table 3).
Pain prevalence ranged from 35.3% to 88.4% in the
studies.1,6,8–12 Two studies tried to identify an association
between pain and sociodemographic characteristics, but did
not ﬁnd any predictors for the development of pain.8,10 The
most frequent pain sites were the lumbar region and the lowerlimbs (Table 2). Lower back pain was considered the worst pain
site, had a negative impact on the Bodily Pain Domain of short-
form (SF-36) and was described as tiring (54.3%) and sickening
(50.0%) by HAM/TSP participants.11 The prevalence of pain in
other body regions was less frequently reported, but included
arthralgia (35.3%),9 upper limbs (25.5%),8 eyes (23.9%),9 head,
face and neck (7.2%), thorax and abdominal regions (4.1%).8
One study distinguished chronic from acute pain and
deﬁned chronic as any pain sustained for a minimum of
three months. In this study, all HAM/TSP individuals suffered
chronic pain and had a longer duration of the disease. Partici-
pants who were followed up for more  than two years reported
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Table 2 – Pain sites and type of subjects in the included studies.
Author, year Pain type (%) Pain site (%)
Low back Low-back and leg pain Lower limbs
Franzoi and Araujo, 2005 – 65.0 –  –
Franzoi and Araujo, 2007 – 65.3 33.3  –
Tavares et al., 2010 Non-neuropathic pain (86.8) 63.2 36.8 –
Netto and Brites, 2011 Non-neuropathic pain (52.6) 36.8 23.7 63.0
Mendes et al., 2013a Neuropathic pain (53.1) 30.0b 63.1 18.2
Martin et al., 2010 – 52.0 26.0 19.0
Poetker et al., 2011 – – – –





































pa This study analyzed pain in HTLV-1 carriers.
b K. Sá, PhD, unpublished data, June, 2015.
he presence of pain more  persistently.10 In a 15-year lon-
itudinal study, 30.0% had become pain free while 25% of
reviously pain free participants reported pain. At presen-
ation and throughout follow-up pain was more  commonly
ersistent than intermittent.12
In three articles, the terms non-neuropathic, nociceptive,
europathic and mixed (both neuropathic and nociceptive
ain) classiﬁed the pain origin. In these cases, the Neu-
opathic Pain 4 Diagnostic Questionnaire (DN4)14 was used
s the screening tool.8,10,11 One study found that neuro-
athic pain was more  common in HTLV-1 carriers irrespective
f the presence of HAM/TSP.8 Other studies assessed only
AM/TSP participants diagnosed according to WHO  criteria,
nd found non-neuropathic pain was the most prevalent type
Table 2).10,11 The presence of neuropathic pain, according
o one study, was associated with a higher prevalence of
isability.10
Pain intensity often ranged from moderate to severe in
AM/TSP participants.10–12 Only one study assessed pain
ntensity in HTLV-1 carriers, and found that 94.0% had moder-
te or severe pain irrespective of the body region. Neuropathic
ain was reported as more  intense than nociceptive pain.8
One study found no difference among HAM/TSP partic-
pants with and without pain using the Kurtzke Expanded
isability Status Scale (EDSS) and the Osame Scale to assess
he impact of the disease. It also described that chronic pain
as associated with a negative impact on SF-36 Quality of Life
QoL), and was worse when present in more  than one body
egion.10
In another study, the most frequent aggravating factor was
ovement, although cold weather, remaining in a same posi-
ion for a long period of time, and physical efforts were also
eported. Drugs and resting were the most frequent factors
eported to relieve pain. This study also found that analgesics,
onsteroidal anti-inﬂammatory (NSAID), and tricyclic antide-
ressants were the most frequently used drugs for relieving
ain.11
iscussionhis paper represents the ﬁrst study to summarize pain char-
cteristics in HTLV-1 infected subjects. Our results show that
ain is frequent and affects predominantly the lumbar regionranging from moderate to intense. It was also found that there
is a larger prevalence of non-neuropathic pain in HAM/TSP,
while neuropathic pain is more  frequent in HTLV-1 carriers
irrespective of the presence of HAM/TSP. Pain was most often
chronic and affected quality of life, but data about its impact
on disability is scarce.
Three papers were classiﬁed as good or very good quality,
while four were considered unsatisfactory. The most frequent
methodological ﬂaws were lack of controls and of representa-
tiveness of the investigated sample, because the studies had a
small sample sizes and the subjects came from only two ref-
erence centers. The heterogeneity of variables prevented us
from conducting a meta-analysis.
The results of these articles regarding pain prevalence
and lower back pain were similar to those which were not
included because of methodological criteria,4,6,15,16 showing
that these characteristics are very consistent in HTLV-1. There
is only one excluded paper where the result was not simi-
lar, but they included children, which was not in the scope
of our review. This ﬁnding suggests that pain may be dif-
ferent between adults and children.16 Consequently, these
results highlight that pain is consistently a problem in HTLV-
1 infection, and that the lower back is the main affected
region.
Regarding the deﬁnition of chronic pain, only one study
deﬁned the period considered to determine the chronicity
of pain – more  than three months.10 Another article did not
clearly reported the used diagnostic criteria for chronic pain,
but chronicity is implied by the long follow-up. Pain in HTLV-1
tends to be chronic, but remission has also been reported.12
As this phenomenon is poorly understood in HTLV-1 sub-
jects, a more  conservative approach in determining a cutoff
point should be considered. The presence of continuous or
frequent pain for more  than six months is in agreement with
the standards of the International Association for the Study
of Pain,17 and should be used in future studies. Chronicity of
pain was expected because neuropathological examinations
evidenced chronic inﬂammatory lesions18 and HTLV-1 infec-
tion and HAM/TSP are chronic diseases without a deﬁnitive
treatment.19The general conception is that the pain in HAM/TSP is
neuropathic, as it is commonly associated with other neuro-
logic symptoms such as paraparesis and urinary disturbance,
but a higher prevalence of this type of pain was found in
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Table 3 – Quality assessment of studies according to Newcastle Ottawa Scale.
Author, year Study design Score NOS Punctuation Failure in studies
Martin et al., 2010 Cohort Very good 7/9 Selection of the non-exposed
cohort; outcome of interesting in
the beginning of study
Poetker et al., 2011 Case Control Very good 9/9 None
Franzoi and Araujo, 2005 Cross-sectional Good 6/10 Sample size; non-respondents;
comparability between groups
Franzoi and Araujo, 2007 Cross-sectional Good 6/10 Sample size; non-respondents;
comparability between groups
Tavares et al., 2010 Cross-sectional Good 5/10 Representativeness of the sample;
sample size; non-respondents;
comparability between groups
Netto and Brites, 2011 Cross-sectional Good 6/10 Sample size; non-respondents;
comparability between groups
Mendes et al., 2013 Cross-sectional Good 5/10 Representativeness of the sample;
sample size; non-respondents;NOS, Newcastle Ottawa Scale.
HTLV-1 infected participants, irrespective of the presence of
HAM/TSP.8
Despite this general concept, two studies found that non-
neuropathic pain was more  common than neuropathic pain
in patients with HAM/TSP.10,11 One study used seven of 10
questions of the DN4, which lowers the cutoff point to deﬁne
neuropathic pain from four to three. As the average DN4 score
in this study was 1.72 (SD 1.50), we assume that a portion of
the patients who  were classiﬁed as non-neuropathic in fact
had neuropathic pain. However, as the prevalence of non-
neuropathic pain was very high (86.8%),11 this most likely
would not change the assumption that non-neuropathic pain
is frequent in HAM/TSP. The second study found a more
balanced distribution between neuropathic (47.3%) and non-
neuropathic pain (estimated to be 52.7%).10 However, it was
not clear if they used seven or 10 questions of the DN4, and
which cutoff point was considered. This may also have altered
the results, but it probably would not dramatically modify
the overall vision that both neuropathic and non-neuropathic
pain are present in HAM/TSP.
The presence of non-neuropathic pain suggests a role
of inﬂammation secondary to the infection in the patho-
physiology of pain in HTLV-1. In general, the inﬂammatory
activity is higher in HAM/TSP than in viral carriers without
myelopathy.20 The release of local and systemic cytokines
associated with inﬂammation mediated by cluster of differ-
entiation antigen 4 (CD4) or CD8 T cells suggest that complex
mechanisms may be involved in HTLV-1 pain. Inﬂammation in
nervous and non-nervous structures is most likely the cause
of the presence of both nociceptive and neuropathic pain, and
these types may differ depending on the body region.21 Pain
is not restricted to lower back and lower limbs and it was
sometimes present in more  than six body regions in the same
subject,8 suggesting that HTLV-1 systemic involvement can
lead to diffuse inﬂammation and pain.
Pain intensity was often moderate to severe in HTLV-1 and
HAM/TSP participants, which suggests that it is misdiagnosed,
misunderstood, and undertreated. Had pain been managed
more adequately, severity would have probably been lower.
The use of analgesics, NSAIDs and tricyclic antidepressantscomparability between groups
in one study was associated with some improvement in pain
control,11 but there are no guidelines for the use of drugs for
the control of symptoms in patients with HTLV-1. Clinical tri-
als to investigate the impact of analgesic procedures in this
population are strongly recommended. In addition to anal-
gesics, these trials should also evaluate other drugs to control
the disease.
Two trials not included in this review reported some
improvement of pain. The ﬁrst used Cyclosporin A in seven
patients for 48 weeks,22 and another used transcranial direct
current stimulation in 20 HTLV-1 infected participants.23 How-
ever, two other trials, one using Zidovudine plus Lamivudine
in a six-month treatment regimen in 16 subjects,24 and the
other using Prednisolone, Pegylated Interferon and Sodium
Valproate in 13 participants for 25 weeks25 did not ﬁnd sig-
niﬁcant differences between drugs and placebo regarding
improvement of pain.
Pilates exercises and physical therapy (with propriocep-
tive neuromuscular facilitation) had clinical relevance in the
control of the lower back pain in HTLV-1 infected patients
and HAM/TSP patients.26,27 This suggests that pain in these
patients may have, in part, a mechanical origin, which needs
to be properly investigated. The major limitations of clinical
trials regarding pain control are small sample sizes and short-
term follow-up.
Two papers presented the impact of pain on quality of life,
but only one was included in this review. However, both pre-
sented similar results showing that HAM/TSP patients with
pain had lower SF-36 QoL scores compared to patients with
the same disease but without pain.10,28 Although pain inten-
sity is considered to be the main outcome in pain studies, the
assessment of quality of life gives relevant information about
the impact of the symptom in daily activities. Future stud-
ies should include QoL assessment along with pain outcomes,
broadening the understanding of how patients deal with this
harming symptom.All studies included in this review came from only two
countries, limiting the external validity of the conclusions.
Further research needs to be done, especially with longitu-
dinal design, with better methodological quality and trials
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ncluding larger number of patients and longer follow-up
eriods.
Our ﬁndings summarize pain characteristics and preva-
ence among patients with HTLV-1, showing that it is common
nd ranges from moderate to severe intensity and affects qual-
ty of life in this population.
unding
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ppendix  A.  Literature  Search  Strategy
Databases searched: PUBMED, SciELO, MEDLINE, LILACS.
Limits: Human.
Filter: No ﬁlter.
1. Pain AND HTLV
2. Pain characteristics AND HTLV
3. Pain prevalence AND HTLV
4. ((Pain) AND HTLV) NOT adult t cell leukemia lymphoma
5. ((Pain) AND (HTLV NOT adult t cell leukemia lymphoma))
NOT HIV
6. ((((Prevalence characteristics) OR pain) AND HTLV) NOT
adult t cell leukemia lymphoma) NOT HIV
7. ((((Neuropathic) AND Nociceptive) OR pain) AND HTLV)
NOT adult t cell leukemia lymphoma
ppendix  B.  Pain  Study  Group  of  Federal
niversity  of  Bahia
ain Study Group includes: Tamires Cristina Martins de Vas-
oncelos, Pedro Larocca Magalhães, Kionna Oliveira Bernardes
antos, Katia Nunes Sá, Fernanda C. Queiros.
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